Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), exhibiting potent inhibitory activity with an IC50 of 3.8 nM and demonstrating 9.0% oral bioavailability (BA). It is utilized in the research of coronavirus disease 2019 (COVID-19) [1].
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約8-10 週間 | ¥ 349,000 |
50 mg | 約8-10 週間 | ¥ 454,500 |
100 mg | 約8-10 週間 | ¥ 574,000 |
説明 | SARS-CoV-2 3CLpro-IN-5 is a covalent inhibitor targeting the 3C-like protease (3CLpro), exhibiting potent inhibitory activity with an IC50 of 3.8 nM and demonstrating 9.0% oral bioavailability (BA). It is utilized in the research of coronavirus disease 2019 (COVID-19) [1]. |
In vitro | SARS-CoV-2 3CLpro-IN-5 exhibits inhibitory activity against 3CL protease with an IC50 of 3.8 nM [1]. This compound also demonstrates antiviral effects in 293TAT cells on multiple SARS-CoV-2 variants—Alpha, Delta, Omicron BA.1, and Omicron BA.2—with corresponding EC50 values of 13.8 nM, 7.57 nM, 9.01 nM, and 17.1 nM [1]. Additionally, it possesses antiviral activity against other coronaviruses—SARS-CoV in 293TAT cells, MERS-CoV in 293TDPP4 cells, and HCoV-OC43 in 293TAT cells—with EC50 values of 59.3 nM, 4.72 nM, and 1.67 nM, respectively [1]. |
In vivo | SARS-CoV-2 3CLpro-IN-5, when administered orally or intravenously at dosages of 10 or 100 mg/kg, exhibits potent antiviral effects and possesses advantageous pharmacokinetic properties [1]. |
分子量 | 497.92 |
分子式 | C22H26ClF2N5O4 |
CAS No. | 2913186-57-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
SARS-CoV-2 3CLpro-IN-5 2913186-57-7 Microbiology/Virology SARS-CoV Inhibitor inhibitor inhibit